Product Substitution

Product substitution is the delivery of a product whose active ingredient is not the one named on the label. It sits alongside adulteration and dilution as a distinct failure mode: the container, carton and documentation may be entirely consistent while the molecule inside is something else. Substitution can be fraudulent, where a cheaper or more easily synthesised compound stands in for an expensive one; it can be an error of labelling or filling in a facility without batch controls; and in falsified supply chains it is often deliberate, since a substituted product need only look and feel plausible to a buyer with no analytical access.

The consequence is not always a weaker product. Regulators and manufacturers investigating counterfeit semaglutide pens in 2023 and 2024 reported units that contained insulin, an entirely different drug with a different dose-response and a real hypoglycaemia risk. A buyer expecting one pharmacology while receiving another is exposed to harm that no dose adjustment can anticipate, and adverse-event reporting attributes the injury to the wrong molecule.

Detecting substitution requires identity confirmation rather than purity testing. Mass spectrometry compares measured molecular mass, and with fragmentation the sequence, against the expected structure; chromatography alone tells you a peak is sharp, not what the peak is. That is why a certificate showing high purity is compatible with a completely substituted product.

The characteristic misreading is treating packaging quality as evidence of contents. Holograms, batch codes, tamper seals and professionally printed cartons are cheap to reproduce and are reproduced. Physical appearance and clean documentation discriminate poorly between an authentic article and a well-executed substitution.